| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Director, 10% Owner
7 companies
Cohen Fred E is a Director at NTLA, with reported holdings spanning 7 companies. Recent filings cover 1 purchase and 3 sales. Those positions are worth an estimated $1.5M at current prices.
Cohen Fred E's largest disclosed position is in BCRX as Director, worth about $742K. The recent filings there lean toward selling, a net 54,250 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | NTLA Intellia Therapeutics, Inc. | Director | Buy | 150,000 | $9.35 | $1,402,500.00 | +261.1% | +41.9% | - | |
| May 18, 2020 | VCYT Veracyte, Inc. | Director | Sell | 40,000 | $26.86 | $1,074,555.36 | -100% | - | - | |
| Sep 18, 2017 | BCRX Biocryst Pharmaceuticals Inc | Director | Sale+OE | 54,250 | $5.42 | $294,035.00 | -31.2% | - | - |